** Shares of telehealth firm Hims & Hers Health HIMS.N fall 7.3% to $53.78 premarket

** Late on Wednesday, health insurer Cigna CI.N said it will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its pharmacy benefit management plans

** "The price point of $200/month is highly attractive compared to other price points in the market, including HIMS' compounded semaglutide at $399/month for 1-month subscription, Wegovy at $899/month for 1-month subscription"- brokerage Truist Securities

** Brokerage adds that HIMS has previously noted "it had very little interest in integrating insurance onto its platform", but, Cigna's weight losscoverage announcement "essentially challenges that argument"

** Brokerage estimates about $721 million of weight-loss drug-related revenues in 2025, which reflects weight-loss revenues and subscribers stepping down sequentially from Q1 to Q2

** Up to last close, stock more than doubled YTD

(Reporting by Sneha S K )

((Sneha.SK@thomsonreuters.com))